Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 08 2023 - 4:05PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
Rachel Haurwitz, PhD, Caribou’s president and chief executive
officer, is scheduled to participate in a fireside chat at the
virtual Oppenheimer 33rd Annual Healthcare Conference on March 15,
2023, at 10:40 am EDT.
Register for the live webcast by visiting the Events page on
Caribou’s website. The webcast will be available on the Caribou
website for 30 days after the event.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its proprietary Cas12a chRDNA
technology, enables superior precision to develop cell therapies
that are armored to potentially improve antitumor activity. Caribou
is advancing a pipeline of off-the-shelf cell therapies from its
CAR-T and CAR-NK platforms as readily available treatments for
patients with hematologic malignancies and solid tumors.
For more information about Caribou, visit www.cariboubio.com and
follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Caribou Biosciences Contacts:
Investors:Amy Figueroa, CFAafigueroa@cariboubio.com
Media:Peggy Vorwald, PhDpvorwald@cariboubio.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024